EVAX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.0B · 46 employees
226
SEC Filings
$3.02
Close 2026-07-13
46
Employees
Business Summary
Evaxion A/S is a Danish TechBio company that develops AI-driven immunology platforms (AI-Immunology) to design vaccine candidates and immunotherapies for oncology and infectious diseases. Its lead asset EVX-B3 was licensed to MSD (Merck & Co.) in 2025 for $7.5 million upfront, with potential milestones and royalties. The company focuses on partnering with large biopharmaceutical companies rather than pursuing late-stage clinical development independently.
Look up EVAX using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on EVAX, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/EVAX (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.